Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple pill help sepsis patients leave the ICU sooner?

NCT ID NCT06319248

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 2 times

Summary

This study tests whether giving the oral drug midodrine early to sepsis patients with low blood pressure can help them stop needing IV blood-pressure medications sooner. Researchers will compare standard care plus midodrine to standard care alone in 308 adults. The goal is to see if this approach shortens time on IV drugs, reduces hospital stays, and makes recovery smoother.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Midodrine (a blood-pressure-raising drug taken by mouth or feeding tube)
What this could lead to
If it works, this could offer a simpler way to wean sepsis patients off IV blood-pressure medications, leading to shorter hospital stays and fewer complications from tubes.
What could go wrong
This is a mid-stage trial with 308 participants, so results are not yet proven. Midodrine may not reduce IV vasopressor use or could cause side effects like high blood pressure or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 308 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: Patients diagnosed with sepsis within 24 hours of meeting all of the following criteria will be eligible to participate in the study: * Sepsis-3 criteria: acute hospital admission for suspected infection with new or worsening organ dysfunction measured by the increase in Sequential Organ failure Assessment (SOFA) score of 2 points or more. * IV vasopressor use or persistent hypotension (MAP \< 65 mm Hg) after initial fluid resuscitation in the ED or ICU (30 mL/kg unless deemed excessive by the treating clinician). Exclusion criteria: * High-dose vasopressors (norepinephrine equivalent \> 0.3 μg/kg/min) * Inadequately controlled source of infection * Cardiogenic or obstructive (massive pulmonary embolism) shock * Clinical suspicion or confirmed diagnosis of bowel obstruction, bowel ischemia, or ileus * Contraindication to enteral intake (ileus, vomiting, gastrointestinal bleeding, endoscopic procedures etc.) * Recent myocardial infarction (STEMI or NSTEMI Type 1 within the past 3 months) * Recent treatment for peripheral vascular disease (within the past 3 months) or acute limb ischemia * Current use of monoamine oxidase inhibitors * Recent stroke (within the past 3 months) * Prior use of midodrine as a home medication * Known allergy to midodrine * Comfort care measures * Pregnancy * Bradycardia (heart rate \< 50 beats/min) * Untreated pheochromocytoma * Untreated thyrotoxicosis * Acute Angle-Closure Glaucoma * Cirrhosis or liver failure with Child-Pugh Score \> 12 * Venous blood lactate \> 4 * Treating emergency or critical care physician unwilling to enroll patient in trial * Inability to give consent for participation and no representative or surrogate available to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Low blood pressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypotensive disorder infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Low blood pressure Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Health System - Eau Claire

    RECRUITING

    Eau Claire, Wisconsin, 54703, United States

  • Mayo Clinic Health System - Mankato

    RECRUITING

    Mankato, Minnesota, 56001, United States

  • Mayo Clinic Minnesota

    RECRUITING

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.